Per the paper (https://www.embopress.org/doi/full/10.15252/emmm.202013714 https://www.embopress.org/doi/full/10.15252/emmm.202013714) the importance of this fin

Per the paper (https://www.embopress.org/doi/full/10.15252/emmm.202013714 https://www.embopress.org/doi/full/10.15252/emmm.202013714) the importance of this finding appears to be the discovery that hFwe-Lose concentration has greater predictive power for patient risk stratification than other methods (which notably include analysis of other biomarkers in addition to things like patient age), at least for patients who will become seriously ill. In other words, working out who is likely to become seriously ill early on is important for physicians to provide the correct level of care; they have a number of tools to perform this asssessment already; the news is that hFwe-Lose concentration seems to be better than the rest at predicting severe outcomes. Personally I don't think it's blindingly obvious that biomarker levels early in the course of a disease should be so very highly predictive of patient outcomes late in the course of a disease, but I am also a layperson.